You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL AND NORELGESTROMIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ethinyl Estradiol And Norelgestromin

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00163072 ↗ Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn Milton S. Hershey Medical Center Phase 4 2005-10-01 Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, particularly in HIV and cancer patients with poor appetite from their primary disease and/or their therapy. Megace is well absorbed orally, however, many patients, particularly younger ones have difficulty taking oral medications. Transdermal progestins are available and are FDA approved. For example, Ortho EvraTM is a transdermal contraceptive patch containing an estrogen (ethinyl estradiol) and a progestin (norelgestromin). Key Objectives: Compare the pharmacokinetics of orally administered vs. transdermal Megace and determine if there are any local side effects of the transdermal route.
NCT00258063 ↗ A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive) Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2004-05-01 The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch manufactured by LOHMANN Therapie-Systeme), to compare these data to exposure data from one clinical lot, and to compare these data to exposure data from a commercially available oral contraceptive.
NCT00258076 ↗ A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch) Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2004-04-01 The objective of this study is to estimate the exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers across multiple commercial lots of ORTHO EVRA® (a transdermal contraceptive patch) and to compare these data to historical hormonal exposure data from one ORTHO EVRA® clinical development lot.
NCT00254865 ↗ A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2002-08-01 The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for Ethinyl Estradiol And Norelgestromin

Condition Name

98300123456789ContraceptionFemale ContraceptionHealthyHeadache, Migraine[disabled in preview]
Condition Name for Ethinyl Estradiol And Norelgestromin
Intervention Trials
Contraception 9
Female Contraception 8
Healthy 3
Headache, Migraine 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

22110-0.200.20.40.60.811.21.41.61.822.2Venous ThromboembolismThromboembolismTissue AdhesionsInfarction[disabled in preview]
Condition MeSH for Ethinyl Estradiol And Norelgestromin
Intervention Trials
Venous Thromboembolism 2
Thromboembolism 2
Tissue Adhesions 1
Infarction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ethinyl Estradiol And Norelgestromin

Trials by Country

+
Trials by Country for Ethinyl Estradiol And Norelgestromin
Location Trials
United States 9
Belgium 2
Netherlands 2
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for Ethinyl Estradiol And Norelgestromin
Location Trials
Florida 1
Wisconsin 1
Texas 1
California 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ethinyl Estradiol And Norelgestromin

Clinical Trial Phase

29.4%5.9%11.8%52.9%0123456789Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for Ethinyl Estradiol And Norelgestromin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

84.2%5.3%5.3%5.3%00246810121416CompletedUnknown statusActive, not recruiting[disabled in preview]
Clinical Trial Status for Ethinyl Estradiol And Norelgestromin
Clinical Trial Phase Trials
Completed 16
Unknown status 1
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ethinyl Estradiol And Norelgestromin

Sponsor Name

trials01234567Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Janssen Research & Development, LLCBoston Medical Center[disabled in preview]
Sponsor Name for Ethinyl Estradiol And Norelgestromin
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 7
Janssen Research & Development, LLC 3
Boston Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

70.8%29.2%0024681012141618IndustryOther[disabled in preview]
Sponsor Type for Ethinyl Estradiol And Norelgestromin
Sponsor Trials
Industry 17
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.